Skip to main content

Table 2 Patient characteristics

From: A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

 

Patients (N = 100)

Characteristics

No.

 

Age, years

  

  Median

 

69

  Range

 

51-92

ECOG performance status

  

  0

91

 

  1

9

 

HLA typing

  

  A24

66

 

  A2

21

 

  A3 supertype

11

 

  A26

2

 

Baseline PSA, ng/ml

  

  Median

 

29.8

  Range

 

0.2-2481

PSADT, months

  

  Median

 

2

  Range

 

0.3-36+

Lymphocyte, 1300/μL

  

  Low

41

 

  High

59

 

CRP, 3 μg/mL

  

  Low

53

 

  High

47

 

SAA, 8 μg/mL

  

  Low

27

 

  High

76

 

IL6, 2.4 pg/mL

  

  Low

84

 

  High

16

 

Gleason score

  

  ≤7

34

 

  ≥8

57

 

  Unknown

9

 

Site of metastasis

  

  no

14

 

  Bone only

33

 

  Bone and nodal/organ

40

 

  Nodal/organ

13

 

Prior chemotherapy

  

  (-)

60

 

  (+)

40

 
  1. Abbreviations: PPV, personalized peptide vaccination; ECOG, Eastern Cooperative Oncology Group; HLA, human leucocyte antigen; PSA, prostate-specific antigen; PSADT, PSA doubling time; CRP, C-reactive protein; SAA, serum amyloid A; IL6, interleukin 6.